Eli Lilly (LLY) Stock Soars as Analysts Boost Price Targets on Weight Loss Drug Momentum

Key Highlights

• JPMorgan increased Eli Lilly’s price target to $1,400 from $1,300 while reaffirming an Overweight rating
• RBC Capital pushed its target to $1,500 from $1,250, keeping an Outperform rating
• Analyst optimism centers on robust performance from Mounjaro and Zepbound weight loss therapies
• New Medicare GLP-1 Bridge initiative, effective July 1, offers Zepbound access for approximately $50 monthly
• Shares currently hover around $1,235, reflecting approximately 14% gains this year and approaching the 52-week peak of $1,249.45

On Tuesday, JPMorgan’s Chris Schott elevated his price objective for Eli Lilly to $1,400 from the previous $1,300 mark, maintaining his bullish Overweight stance. This revised forecast significantly exceeds the Street’s consensus estimate of approximately $1,305.

Eli Lilly and Company, LLY

Coinciding with the analyst upgrade, shares touched a new 52-week peak. Schott identified Lilly as his preferred healthcare sector investment.

RBC Capital simultaneously announced its own adjustment Tuesday, elevating the price target to $1,500 from $1,250 while preserving its Outperform designation. The firm noted its internal revenue forecasts exceed consensus by approximately 1%, with Zepbound and Mounjaro performance surpassing expectations by 5%-6%.

Eli Lilly shares are currently changing hands near $1,235, representing gains of roughly 7.5% over the last 30 days and approximately 14% since January. The stock’s 52-week floor stands at $623.78.

Schott forecasted second-quarter revenue totaling approximately $20.7 billion for Lilly, exceeding consensus by roughly $300 million. He identified two primary catalysts: Mounjaro’s international market penetration and sustained domestic Zepbound demand.

During the first quarter of 2026, Lilly delivered $19.8 billion in revenue, marking a 55.5% year-over-year surge. The Mounjaro and Zepbound duo generated approximately $12.8 billion in worldwide sales during that period. Domestic revenue climbed 43% to $12.1 billion, propelled by a 49% volume increase.

Following these strong results, Lilly elevated its 2026 full-year revenue outlook to a range between $82 billion and $85 billion.

Medicare Initiative Creates Expanded Market Opportunity

Beginning July 1, Medicare’s newly launched GLP-1 Bridge initiative extended coverage for Zepbound and the oral medication Foundayo to qualifying beneficiaries at monthly costs as low as $50. Given approximately 20 million Medicare enrollees may meet eligibility criteria, certain market observers believe even the $1,400 projection might underestimate potential upside.

Enhanced affordability generally stimulates prescription volume growth, directly influencing the revenue metrics analysts monitor closely.

Volume expansion has successfully counterbalanced the reduced U.S. pricing Lilly implemented, aligning precisely with management’s previous guidance to shareholders.

Development Portfolio Strengthens Investment Thesis

Beyond existing commercial blockbusters, Schott emphasized Lilly’s development pipeline as an additional confidence driver. Notable experimental candidates include orforglipron, the oral GLP-1 now marketed as Foundayo, plus retatrutide, a triple-receptor agonist in clinical testing. Schott estimates the combined potential market for these therapies exceeds $200 billion.

Competitive disappointments have simultaneously benefited Lilly’s market standing. Disappointing clinical outcomes from emerging competitors have solidified Lilly’s dominant position, reinforcing what market watchers describe as substantial competitive advantages.

Lilly’s market capitalization currently approaches $1.16 trillion, with the stock trading at approximately 44 times earnings.

The next critical milestone arrives August 5, when the company unveils second-quarter financial performance. RBC observed strong prescription volume momentum across U.S. and international markets, anticipating pricing pressures in the low-to-mid-teen percentage range.

Schott anticipates Q2 results could exceed expectations, although shares trading near all-time highs create elevated performance expectations on both fundamental and market fronts.